Nome Químico: 6-O-Methyl Erythromycin N-Oxide
Sinônimo: Clarithromycin N-Oxide
Sorrisos: C[C@@H]([C@@H]([C@H](C(O[C@@H]1CC)=O)C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@@](C)(C[C@H](C([C@@H]([C@@H](O)[C@@]1(O)C)C)=O)C)OC)O[C@@](O[C@H](C)C[C@@H]3[N](C)(C)=O)([H])[C@@H]3O
Inchi: InChI=1S/C39H71NO13/c1-16-27-39(10,45)32(43)22(4)29(41)20(2)18-37(8,47-14)33(53-36-30(42)26(40(11)12)17-21(3)49-36)23(5)31(24(6)35(44)51-27)52-28-19-38(9,48-15)34(46-13)25(7)50-28/h20-28,30-34,36,42-43,45H,16-19H2,1-15H3/t20-,21-,22?,23+,24-,25+,26+,27?,28+,30-,31?,32-,33-,34+,36+,37-,38-,39-/m1/s1
Stability indicating HPLC-ECD method for the analysis of clarithromycin in pharmaceutical dosage forms: method scaling versus re-validation
By Makoni, Pedzisai A.; Chikukwa, Mellisa T. R.; Khamanga, Sandile M. M.; Walker, Roderick B.
From Scientia Pharmaceutica (2019), 87(4), 31
Stability indicating Rp-Hplc method development and validation for the simultaneous estimation of gemcitabine and clarithromycin in bulk and pharmaceutical dosage form
By Kumar, Y. Anil; Sirisha, Y.; Harini, A. L.; Prathyusha, A.
From World Journal of Pharmaceutical Research (2018), 7(8Spec.Iss.), 1-8
Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model
By Zhang Xia; Hu Changqin
From Journal of pharmaceutical and biomedical analysis (2017), 136, 162-169